Morphic to Present at the Canaccord Genuity 43rd Annual Growth Conference
09 Agosto 2023 - 5:05PM
Morphic Therapeutic (Nasdaq: MORF), a biotechnology company
developing a new generation of oral integrin therapies for the
treatment of serious chronic diseases, today announced that Praveen
Tipirneni, M.D., President and Chief Executive Officer, will take
part in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth
Conference on Thursday, August 10, 2023 at 11:30 AM ET.
A live webcast of the presentation will be
available on the Investor section of Morphic’s website
at www.morphictx.com. An archived replay will be available on
the company’s website following the conference.
About Morphic
TherapeuticMorphic Therapeutic is a biopharmaceutical
company developing a portfolio of oral integrin therapies for the
treatment of serious chronic diseases, including autoimmune,
cardiovascular, and metabolic diseases, fibrosis, and cancer.
Morphic is also advancing its pipeline and discovery activities in
collaboration with Schrödinger using its proprietary MInT
technology platform which leverages the Company’s unique
understanding of integrin structure and biology. For more
information, visit www.morphictx.com.
ContactsMorphic
TherapeuticChris Erdmanchris.erdman@morphictx.com617.686.1718
Morphic (NASDAQ:MORF)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Morphic (NASDAQ:MORF)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024